Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PLSE |
---|---|---|
09:32 ET | 548 | 17.22 |
09:36 ET | 200 | 17.59 |
09:38 ET | 100 | 17.59 |
09:39 ET | 100 | 17.87 |
09:43 ET | 100 | 17.83 |
09:45 ET | 3500 | 17.3543 |
09:48 ET | 500 | 17.635 |
09:50 ET | 700 | 17.66 |
09:52 ET | 1100 | 17.67 |
09:54 ET | 800 | 17.79 |
09:59 ET | 1200 | 18 |
10:01 ET | 200 | 17.899 |
10:03 ET | 700 | 18.05 |
10:06 ET | 505 | 18.15 |
10:08 ET | 100 | 18.18 |
10:10 ET | 100 | 18.2199 |
10:15 ET | 951 | 18.181 |
10:17 ET | 100 | 17.91 |
10:24 ET | 350 | 17.98 |
10:26 ET | 110 | 18.096 |
10:30 ET | 561 | 17.94 |
10:32 ET | 600 | 18.0744 |
10:33 ET | 228 | 17.945 |
10:37 ET | 1599 | 17.66 |
10:57 ET | 1100 | 17.72 |
11:08 ET | 998 | 17.82 |
11:18 ET | 1952 | 17.91 |
11:20 ET | 280 | 18.0299 |
11:24 ET | 100 | 17.85 |
11:27 ET | 700 | 17.96 |
11:31 ET | 7729 | 18.19 |
11:33 ET | 500 | 18.29 |
11:42 ET | 100 | 18.53 |
11:47 ET | 700 | 18.51 |
11:49 ET | 400 | 18.68 |
11:51 ET | 1000 | 18.3913 |
11:54 ET | 2045 | 18.663 |
11:56 ET | 1765 | 18.42 |
11:58 ET | 1700 | 18.25 |
12:18 ET | 430 | 18.285 |
12:23 ET | 743 | 18.3091 |
12:25 ET | 400 | 18.3707 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pulse Biosciences Inc | 1.1B | -23.2x | --- |
Nano-X Imaging Ltd | 362.7M | -6.2x | --- |
Simulations Plus Inc | 656.5M | 68.2x | +3.18% |
Atlantic International Corp | 272.9M | -0.6x | --- |
Orchestra Biomed Holdings Inc | 215.2M | -3.6x | --- |
Clearpoint Neuro Inc | 336.9M | -17.2x | --- |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-0.79 |
Book Value | $0.80 |
P/E Ratio | -23.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.